What's behind GSK's massive earnings and will the stock price surge continue?
Over the past 12 months, Pakistan’s pharmaceutical sector has delivered stellar stock performance
Over the past 12 months, Pakistan’s pharmaceutical sector has delivered stellar stock performance, driven by long-overdue regulatory relief, including significant price hikes in 2023–2024.
This shift came after years of capped prices, surging API costs, and currency depreciation that had severely squeezed margins.
GSK Pakistan, in particular, posted dramatic earnings rebound — from PKR 534 million in 2023 to over PKR 6.5 billion in 2024 — led by improved pricing and margin expansion.
Watch the full video for a comprehensive pharma industry analysis and stock analysis of GSK.
Popular
Spotlight
More from Business
Pakistan extends PKR 50 billion sovereign guarantee for LNG payments
ECC greenlights financial support for energy initiatives, including nationwide efficiency program and distribution sector reforms
More from Video
Dubai Bling’s Diva Dee on backlash, grace and staying classy
From the spotlight to soul, Danya shared it all
Comments
See what people are discussing